Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
about
Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update.FGF21 inhibitor suppresses the proliferation and migration of human umbilical vein endothelial cells through the eNOS/PI3K/AKT pathway.A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.Precision medicine applications in prostate cancer.
P2860
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Presence of both alterations i ...... with PI3K/AKT/mTOR inhibitors
@ast
Presence of both alterations i ...... with PI3K/AKT/mTOR inhibitors
@en
type
label
Presence of both alterations i ...... with PI3K/AKT/mTOR inhibitors
@ast
Presence of both alterations i ...... with PI3K/AKT/mTOR inhibitors
@en
prefLabel
Presence of both alterations i ...... with PI3K/AKT/mTOR inhibitors
@ast
Presence of both alterations i ...... with PI3K/AKT/mTOR inhibitors
@en
P2093
P2860
P50
P356
P1433
P1476
Presence of both alterations i ...... with PI3K/AKT/mTOR inhibitors
@en
P2093
Jennifer J Wheler
Johnique T Atkins
Philip J Stephens
Roman Yelensky
Stacy L Moulder
Vicente Valero
Vincent Miller
P2860
P304
P356
10.18632/ONCOSCIENCE.307
P577
2016-06-30T00:00:00Z